KR900001847A - 항응고 폴리펩티드 - Google Patents

항응고 폴리펩티드 Download PDF

Info

Publication number
KR900001847A
KR900001847A KR1019890010107A KR890010107A KR900001847A KR 900001847 A KR900001847 A KR 900001847A KR 1019890010107 A KR1019890010107 A KR 1019890010107A KR 890010107 A KR890010107 A KR 890010107A KR 900001847 A KR900001847 A KR 900001847A
Authority
KR
South Korea
Prior art keywords
nucleotide sequence
dna fragment
amino acid
sequence
polypeptide
Prior art date
Application number
KR1019890010107A
Other languages
English (en)
Other versions
KR970005913B1 (ko
Inventor
아끼오 이와사끼
마꼬또 수다
유시 사이노
Original Assignee
미와 다까야수
코와 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미와 다까야수, 코와 가부시끼 가이샤 filed Critical 미와 다까야수
Publication of KR900001847A publication Critical patent/KR900001847A/ko
Application granted granted Critical
Publication of KR970005913B1 publication Critical patent/KR970005913B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

항응고 폴리펩티드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 X가 메티오닐 잔기(Met), 아세틸 또는 수소원자인 본 발명의 폴리펩티드의 아미노산 서열을 나타내고,
제2도는 본 발명의 cDNA의 뉴클레오티드 서열을 나타내고,
제3도는 본 발명의 cDNA삽입 단편의 제한 엔도뉴클레아제 맵(map)을 제공한다.

Claims (9)

  1. 제1도에 나타낸 아미노산 서열을 갖는 폴리 팹티드.
  2. 제1도에 나타낸 아미노산 서열을 코딩한 뉴클레오티드 서열을 갖는 DNA단편.
  3. 제2항에 있어서, 뉴클레오티드 서열이 제2도에 나타낸 것인 DNA단편.
  4. 제2항 또는 제3항에 있어서, DNA단편에 상보적인 뉴클레오티드 서열을 갖는 DNA단편.
  5. 하기 (1) 및 (2)로 구성되는 재조합 플라스미드 : (1) 제1도에 나타낸 아미노산 서열을 코딩하는 뉴클레오티드 서열을 갖는 DNA단편 및/또는 상기 뉴클레오티드 서열에 상보적인 뉴클레오티드 서열을 갖는 DNA 단펴 ; (2)복제능이 있는 벡터 DNA
  6. 전사되는 아래방향으로 다음 뉴클레오티드 서열(1)-(6)의 순서를 갖는 재조합 플라스미드 ;(1)프로모터로 작용하는 뉴클레오티드 서열, (2) 리보좀 결합 부위인 뉴클레오티드 서열, (3) 개시 코돈인 뉴클레오티드 서열, (4) 제1도에 나타낸 바의 아미노산의 아미노산 서열을 코딩할 수 있는 뉴클레오티드 서열. (5) 종결 코돈인 뉴클레오티드 서열, (6) 전사 터미네이터로 작용하는 뉴클레오티드 서열.
  7. 제5항 또는 제6항에 기재된 플라스미드를 함유하는 형질전환체.
  8. 제1항에 기재된 폴리팹티드를 유효성분으로 함유하는 항응고제.
  9. 제7항에 기재된 형질 전환체를 배양한 후, 배양물로부터 생산된 폴리팹티드를 수집함을 특징으로 하는 제1항 개재의 폴리팹티드의 생산 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890010107A 1988-07-21 1989-07-15 항혈액응고 작용을 갖는 폴리펩티드 KR970005913B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP63182633A JP2701047B2 (ja) 1988-07-21 1988-07-21 抗血液凝固作用を有するポリペプチド
JP182633/1988 1988-07-21
JP63-182633 1988-07-21

Publications (2)

Publication Number Publication Date
KR900001847A true KR900001847A (ko) 1990-02-27
KR970005913B1 KR970005913B1 (ko) 1997-04-22

Family

ID=16121703

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890010107A KR970005913B1 (ko) 1988-07-21 1989-07-15 항혈액응고 작용을 갖는 폴리펩티드

Country Status (6)

Country Link
EP (1) EP0351826B1 (ko)
JP (1) JP2701047B2 (ko)
KR (1) KR970005913B1 (ko)
CA (1) CA1338401C (ko)
DE (1) DE68918519T2 (ko)
ES (1) ES2064391T3 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
CA2190727C (en) * 1994-05-19 2006-07-18 Sudhakar Kasina Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
DE10162434A1 (de) * 2001-12-18 2003-09-25 November Ag Molekulare Medizin Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors
KR20100020236A (ko) * 2008-08-12 2010-02-22 세기 리미티드 센서를 구비한 차량용 무선통신장치 및 차량 제어시스템

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764878B2 (ja) * 1986-10-14 1995-07-12 興和株式会社 抗血液凝固物質及びその製法

Also Published As

Publication number Publication date
DE68918519D1 (de) 1994-11-03
EP0351826B1 (en) 1994-09-28
JPH0232099A (ja) 1990-02-01
DE68918519T2 (de) 1995-05-11
ES2064391T3 (es) 1995-02-01
JP2701047B2 (ja) 1998-01-21
CA1338401C (en) 1996-06-18
EP0351826A3 (en) 1990-05-23
KR970005913B1 (ko) 1997-04-22
EP0351826A2 (en) 1990-01-24

Similar Documents

Publication Publication Date Title
KR910003101A (ko) β-1, 3-글루카나제 활성을 갖는 폴리펩티드를 코딩하는 DNA 서열
DK0423302T3 (da) Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner
KR880007734A (ko) 폴리펩타이드 유도체
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
RU2004126135A (ru) Новый цитокин zalpha11-лиганд
EP1571221A3 (en) Genes involved in tolerance to environmental stress
IL97566A0 (en) Antigenic proteins,their production and their use in the prevention of coccidiosis
KR840004781A (ko) 인체의 조직 플라스미노겐 활성화제
KR850006550A (ko) 단백질의 제조방법
KR880009991A (ko) 항혈액응고작용을 갖는 폴리펩티드
KR900001847A (ko) 항응고 폴리펩티드
YU172185A (en) Process for obtaining monoclonic anti-bodies
IN187721B (ko)
SE8204811L (sv) Dna-fragment innefattande en signalsekvens
KR970001542A (ko) 엔도글리코세라미데이즈 유전자
KR910016923A (ko) 트롬빈 결합성 물질의 제조법
ATE145004T1 (de) Verfahren zur herstellung von luciferase durch rekombinante expression eines luciferase- kodierenden gens
KR890008166A (ko) 융합 단백질의 선택적 분해 방법
KR850001286A (ko) 개량 플라스미드 벡타의 제조방법
EP0183272A3 (en) Vector capable of efficient gene expression and utilization of such vector
KR920004577A (ko) 단백질 합성의 cks 방법
KR910000180A (ko) 트롬빈 억제 활성을 갖는 폴리펩티드 및 그의 제조방법
KR860002568A (ko) 인터페론 활성을 갖는 폴리펩타이드의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee